Articles by Tim Freeman - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Tim Freeman

Tableting—a Focus for Continuous Improvement

Aug 1, 2014

Efforts to tackle challenges in tablet manufacture are shaped by quality by design (QbD) and continuous manufacturing.

Powder Testing Techniques for Tablet Manufacture

This article considers the different conditions to which the powder is subjected in the tableting process, and discusses which powder properties should be measured to accurately reflect likely powder behavior in the process.
Mar 1, 2012

This article considers the different conditions to which the powder is subjected in the tableting process, and discusses which powder properties should be measured to accurately reflect likely powder behavior in the process.

Under Continuous Consideration

Continuous manufacturing is increasingly noted as an important long-term objective for the pharmaceutical industry. PTE talks with Tim Freeman, Director of Operations at Freeman Technology, about some of the central issues involved in this transition, as well as the supporting role of relevant analytical technology.
Nov 1, 2011

Continuous manufacturing is increasingly noted as an important long-term objective for the pharmaceutical industry. PTE talks with Tim Freeman, Director of Operations at Freeman Technology, about some of the central issues involved in this transition, as well as the supporting role of relevant analytical technology.

Correlating Die-Filling Performance with Powder Properties

The author explains how to gain an understanding of the relationships between powder characteristics and process performance to match filling-machine geometry to the demands of specific formulations.
Apr 1, 2011

The author explains how to gain an understanding of the relationships between powder characteristics and process performance to match filling-machine geometry to the demands of specific formulations.

Establishing Endpoints

Mar 7, 2011

The unit selected for wet granulation, whether it be a high shear mixer or a fluidised bed, has a marked impact on granule properties.

Applying Real Time Release Testing to Powder Processing

How to adapt a real time release approach to powder processing during drug-product manufacturing.
Feb 2, 2011

How to adapt a real time release approach to powder processing during drug-product manufacturing.

The importance of powder characterization

Effective powder characterisation can lead to better powder understanding and control, which is crucial in the pharma industry where the majority of APIs are delivered as powders. Tim Freeman explains why powder characterisation is not always an easy task and offers advice on how best to obtain rich data sets that can be used to predict powder behaviour in different situations.
Jun 1, 2010

How effective powder characterization can lead to better powder understanding and control.

Understanding powder behaviour

May 1, 2010

The needs of the pharmaceutical industry for powder testing technologies are changing, primarily for two reasons.

Understanding powder behaviour

May 1, 2010

The needs of the pharmaceutical industry for powder testing technologies are changing, primarily for two reasons. The first is that global economics, and the economics and competitiveness of the pharmaceutical industry itself, are driving manufacturers towards achieving greater efficiency.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here